Axsome Therapeutics, Inc. (AXSM) SEC Filing 8-K Material Event for the period ending Wednesday, October 2, 2019

Axsome Therapeutics, Inc.

CIK: 1579428 Ticker: AXSM

View differences made from one to another to evaluate Axsome Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Axsome Therapeutics, Inc..


Assess how Axsome Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Axsome Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Material Contracts, Statements, Certifications & more

Axsome Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: AXSM
CIK: 1579428
Form Type: 8-K Corporate News
Accession Number: 0001104659-19-052389
Submitted to the SEC: Wed Oct 02 2019 7:06:10 AM EST
Accepted by the SEC: Wed Oct 02 2019
Period: Wednesday, October 2, 2019
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: